ALSO NOTED: J&J recalls children's Tylenol; PharmaFrontiers releases Phase I/II data; XenoPort cuts IPO price; and much mor

> Johnson & Johnson says it is recalling children's Tylenol out of concern that its packaging could lead to overdosing. Story

> PharmaFrontiers has released positive interim data from two Phase I/II trials of multiple sclerosis. Release

> Santa Clara, California-based XenoPort cut the share price of its IPO to $10.50, down from an initial range of $14 to $16 per share. XenoPort is focused on improving the efficacy of existing drugs. Story

> BioDelivery Systems International has rounded up $2.5 million in new financing. Release

> The UK's TranXenogen says that the buyer for its building has pulled out of negotiations. Story

> Vancouver-based InNexus Biotechnology has announced it has expanded its intellectual property portfolio. Release 

And Finally... For the first time, the CDC has studied an outbreak of obesity as it would track an infectious disease. Story

Suggested Articles

Biotech leaders criticized the dismissals of Chinese scientists from U.S. universities in a letter with more than 150 signatures.

In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. 

In our EuroBiotech roundup this week, Scancell withdraws IND, Oxurion’s eye drug fails phase 2a and Abivax starts ulcerative colitis trial.